CN1440387A - α结晶形式的哌林多普利叔丁基胺盐 - Google Patents

α结晶形式的哌林多普利叔丁基胺盐 Download PDF

Info

Publication number
CN1440387A
CN1440387A CN01812354A CN01812354A CN1440387A CN 1440387 A CN1440387 A CN 1440387A CN 01812354 A CN01812354 A CN 01812354A CN 01812354 A CN01812354 A CN 01812354A CN 1440387 A CN1440387 A CN 1440387A
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutical composition
ethyl acetate
cooled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN01812354A
Other languages
English (en)
Other versions
CN1328259C (zh
Inventor
B·普法伊费尔
Y－M·吉诺
G·科克雷尔
S·贝耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8852172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1440387(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of CN1440387A publication Critical patent/CN1440387A/zh
Application granted granted Critical
Publication of CN1328259C publication Critical patent/CN1328259C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明涉及α结晶形式的式(I)化合物，其特征在于其粉末X射线衍射图案。本发明可用于制备药物。

Description

α结晶形式的哌林多普利叔丁基胺盐
本发明涉及新的α结晶形式的式(I)哌林多普利叔丁基胺盐：
Figure A0181235400041
其制备方法以及包含它的药物组合物。
哌林多普利及其可药用盐，更具体地说是其叔丁基胺盐，具有有价值的药理学性能。
它们的主要性能是抑制血管紧张素I转化酶(或激肽酶II)，后者一方面防止十肽血管紧张素I向八肽血管紧张素II(血管收缩药)转化且另一方面防止缓激肽(血管舒张药)降解成无活性肽。
这两个作用有助于哌林多普利在心血管疾病，更尤其是动脉高血压和心力衰竭中的有益效果。
哌林多普利、其制备及其在治疗剂中的用途已经描述于欧洲专利说明书EP 0 049 658中。
鉴于该化合物的药物价值，最重要的是以优异纯度得到它。也重要的是能够通过可容易地转化成工业规模的方法，尤其以允许快速过滤和干燥的形式合成它。最后，该形式必须完全可再现、易于配制且足够稳定以允许其长期储存而对温度、光、湿度或氧含量没有特别要求。
专利说明书EP 0 308 341描述了一种用于哌林多普利的工业合成方法。然而，该文献并没有说明以可再现地显示这些特征的形式得到哌林多普利的条件。
本申请的申请人现已发现哌林多普利的特定盐—叔丁基胺盐—可以良好限定的、完全可再现的结晶形式得到，该形式在过滤、干燥和配制容易性上显示出有价值的特性。
更具体地说，本发明涉及α结晶形式的式(I)化合物，其特征在于其具有使用Siemens D5005衍射仪(铜对阴极)测量并以晶面间距d、布拉格角2θ、强度和相对强度(以最强射线的百分数表达)表达的以下粉末X射线衍射图：
    2θ角(°)   晶面间距d()     强度   相对强度(％)
    7.680     11.50     390     8.8
    8.144     10.85     230     5.2
    9.037     9.78     4410     100
    10.947     8.08     182     4.1
    13.150     6.73     82     1.9
    13.687     6.46     83     1.9
    14.627     6.05     582     13.2
    15.412     5.74     770     17.5
    16.573     5.34     1115     25.3
    17.357     5.10     340     7.7
    18.109     4.89     193     4.4
    19.922     4.45     306     6.9
    20.609     4.31     375     8.5
    21.412     4.15     226     5.1
    21.832     4.07     217     4.9
    22.158     4.01     483     11
    22.588     3.93     386     8.8
    23.323     3.81     107     2.4
    24.200     3.67     448     10.2
    24.727     3.60     137     3.1
    25.957     3.43     125     2.8
    26.932     3.31     75     1.7
    27.836     3.20     197     4.5
    28.966     3.08     129     2.9
    29.213     3.05     117     2.7
本发明还涉及一种制备α结晶形式的式(I)化合物的方法，该方法的特征在于在回流下加热哌林多普利叔丁基胺盐在乙酸乙酯中的溶液，然后将溶液逐渐冷却至结晶完全。
·在根据本发明的结晶方法中，可以使用由任何方法得到的式(I)化合物。有利的是使用由专利说明书EP 0 308 341中所述的制备方法得到的式(I)化合物。
·式(I)化合物在乙酸乙酯中的浓度优选为70-90g/升。
·有利的是，首先将式(I)化合物在乙酸乙酯中在回流下的溶液以5-10℃/小时，优选6-8℃/小时的速率冷却至55-65℃的温度，然后冷却至室温。
·有利的是可在76-65℃温度下的冷却步骤过程中向溶液中放入晶种。
·如此得到的哌林多普利叔丁基胺盐呈长约0.2mm的单个针状物。该均相分布的优点在于允许尤其快速和有效的过滤和干燥且允许制备具有均匀和可再现组成的药物制剂，这在这些制剂意欲用于口服给药时尤为有利。
·如此得到的形式足够稳定，从而允许长期储存而对温度、光、湿度或氧含量没有特殊要求。
本发明还涉及药物组合物，其包含α结晶形式的式(I)化合物作为活性成分以及一种或多种合适的惰性、无毒赋形剂。在本发明的药物组合物中，可以更具体提及适于口服、胃肠外(静脉内或皮下)或经鼻给药的那些、片剂或糖锭剂、舌下片剂、明胶胶囊、锭剂、栓剂、霜剂、软膏、皮肤凝胶、可注射制剂、可饮用悬浮液等。
有用的剂量可以根据疾病的性质和严重程度、给药途径以及患者的年龄和体重而变化。它在1-500mg/天内变化，以一次或多次给药。
本发明的药物组合物也可包含利尿药如吲满胺。
下列实施例说明本发明但决不限制本发明。
在下列实验条件下测量粉末X射线衍射光谱：
—Siemens D5005衍射仪，闪烁探测器，
—铜对阴极(λ＝1.5405)，电压40kV，强度40mA，
—安装θ-θ，
—测量角：5-30°，
—在各次测量之间的增量：0.02°，
—每步的测量时间：2秒，
—可变狭缝：v6，
—滤光器Kβ(Ni)，
—无内标，
—使用Siemens狭缝的调零程序，
—使用EVA软件(5.0版)处理实验数据。实施例1：α结晶形式的哌林多普利叔丁基胺盐
将125g根据专利说明书EP 0 308 341所述的方法得到的哌林多普利叔丁基胺盐溶于1.68升在回流下加热的乙酸乙酯中。
然后使该溶液温度在2小时30分钟内达到60℃，之后冷却至室温。通过过滤收集所得固体。粉末X射线衍射图：
α形式的哌林多普利叔丁基胺盐的粉末X射线衍射图案(衍射角)由在下表中分类的有效射线以及强度和相对强度(以最强射线的百分数表达)给出：
    2θ角(°)   晶面间距d()    强度   相对强度(％)
    7.680     11.50     390     8.8
    8.144     10.85     230     5.2
    9.037     9.78     4410     100
    10.947     8.08     182     4.1
    13.150     6.73     82     1.9
    13.687     6.46     83     1.9
    14.627     6.05     582     13.2
    15.412     5.74     770     17.5
    16.573     5.34     1115     25.3
    17.357     5.10     340     7.7
    18.109     4.89     193     4.4
    19.922     4.45     306     6.9
    20.609     4.31     375     8.5
    21.412     4.15     226     5.1
    21.832     4.07     217     4.9
    22.158     4.01     483     11
    22.588     3.93     386     8.8
    23.323     3.81     107     2.4
    24.200     3.67     448     10.2
    24.727     3.60     137     3.1
    25.957     3.43     125     2.8
    26.932     3.31     75     1.7
    27.836     3.20     197     4.5
    28.966     3.08     129     2.9
    29.213     3.05     117     2.7
实施例2：药物组合物
制备1000片各含4mg活性成分的片剂的配方：
实施例1的化合物.................................4g
羟丙基纤维素....................................2g
小麦淀粉........................................10g
乳糖............................................100g
硬脂酸镁........................................3g
滑石............................................3g

Claims (13)

1.α结晶形式的式(I)化合物：
Figure A0181235400021
其特征在于其具有使用衍射仪(铜对阴极)测量并以晶面间距d、布拉格角2θ、强度和相对强度(以相对于最强射线的百分数表达)表达的以下粉末X射线衍射图：     2θ角(°)   晶面间距d()     强度   相对强度(％)     7.680     11.50     390     8.8     8.144     10.85     230     5.2     9.037     9.78     4410     100     10.947     8.08     182     4.1     13.150     6.73     82     1.9     13.687     6.46     83     1.9     14.627     6.05     582     13.2     15.412     5.74     770     17.5     16.573     5.34     1115     25.3     17.357     5.10     340     7.7     18.109     4.89     193     4.4     19.922     4.45     306     6.9     20.609     4.31     375     8.5     21.412     4.15     226     5.1     21.832     4.07     217     4.9     22.158     4.01     483     11     22.588     3.93     386     8.8     23.323     3.81     107     2.4     24.200     3.67     448     10.2     24.727     3.60     137     3.1     25.957     3.43     125     2.8     26.932     3.31     75     1.7
    27.836     3.20     197     4.5     28.966     3.08     129     2.9     29.213     3.05     117     2.7
2.制备根据权利要求1的α结晶形式的式(I)化合物的方法，其特征在于在回流下加热哌林多普利叔丁基胺盐在乙酸乙酯中的溶液，然后将溶液逐渐冷却直至结晶完全。
3.根据权利要求2的方法，其特征在于使用通过专利说明书EP 0 308341中所述的制备方法得到的式(I)化合物。
4.根据权利要求2或3的方法，其特征在于式(I)化合物在乙酸乙酯中的浓度为70-90g/升。
5.根据权利要求2-4中任一项的方法，其特征在于首先将式(I)化合物在乙酸乙酯中在回流下的溶液以5-10℃/小时的速率冷却至55-65℃的温度，然后冷却至室温。
6.根据权利要求2-4中任一项的方法，其特征在于在76-65℃温度下的冷却步骤过程中向式(I)化合物在乙酸乙酯中的溶液中放入晶种。
7.根据权利要求5的方法，其特征在于首先将式(I)化合物在乙酸乙酯中在回流下的溶液以6-8℃/小时的速率冷却至55-65℃的温度，然后冷却至室温。
8.根据权利要求2-7中任一项的方法，其特征在于如此得到的哌林多普利叔丁基胺盐呈易于过滤的单个针状物形式。
9.药物组合物，包含根据权利要求1的化合物作为活性成分以及一种或多种可药用的惰性、无毒载体。
10.根据权利要求9的药物组合物，用于制造用作血管紧张素I转化酶的抑制剂的药物。
11.根据权利要求10的药物组合物，用于制造用于治疗心血管疾病的药物。
12.根据权利要求9-11中任一项的药物组合物，其特征在于它还包含利尿药。
13.根据权利要求12所述的药物组合物，其特征在于利尿药为吲满胺。
CNB018123546A 2000-07-06 2001-07-06 α结晶形式的哌林多普利叔丁基胺盐 Ceased CN1328259C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0008793A FR2811320B1 (fr) 2000-07-06 2000-07-06 Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR00/08793 2000-07-06

Publications (2)

Publication Number Publication Date
CN1440387A true CN1440387A (zh) 2003-09-03
CN1328259C CN1328259C (zh) 2007-07-25

Family

ID=8852172

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018123546A Ceased CN1328259C (zh) 2000-07-06 2001-07-06 α结晶形式的哌林多普利叔丁基胺盐

Country Status (35)

Country Link
US (2) US20030186896A1 (zh)
EP (1) EP1296947B1 (zh)
JP (2) JP3602826B2 (zh)
KR (1) KR100513570B1 (zh)
CN (1) CN1328259C (zh)
AP (1) AP1537A (zh)
AR (1) AR034124A1 (zh)
AT (1) ATE258918T1 (zh)
AU (2) AU2001276418B2 (zh)
BG (1) BG64868B1 (zh)
BR (1) BR0112367A (zh)
CA (1) CA2415438C (zh)
CZ (1) CZ297672B6 (zh)
DE (1) DE60101968T2 (zh)
DK (1) DK1296947T3 (zh)
EA (1) EA005008B1 (zh)
EE (1) EE05268B1 (zh)
ES (1) ES2214434T3 (zh)
FR (1) FR2811320B1 (zh)
GE (1) GEP20043361B (zh)
HK (1) HK1055425A1 (zh)
HR (1) HRP20030077B1 (zh)
ME (1) ME00443B (zh)
MX (1) MXPA02012949A (zh)
NO (1) NO323447B1 (zh)
NZ (1) NZ523173A (zh)
OA (1) OA12304A (zh)
PL (1) PL206359B1 (zh)
PT (1) PT1296947E (zh)
RS (1) RS50915B (zh)
SK (1) SK285714B6 (zh)
TR (1) TR200400238T4 (zh)
UA (1) UA57188C2 (zh)
WO (1) WO2001087835A1 (zh)
ZA (1) ZA200210092B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105395497A (zh) * 2015-12-04 2016-03-16 杭州新诺华医药有限公司 一种稳定的α晶型培哚普利叔丁胺片及制备方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2811318B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811319B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2838648B1 (fr) * 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
GB2395195A (en) 2002-11-18 2004-05-19 Cipla Ltd Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors
KR20060035636A (ko) * 2003-06-24 2006-04-26 르 라보레또레 쎄르비에르 신규한 결정형의 페린도프릴 에르부민
WO2005037788A1 (en) * 2003-10-21 2005-04-28 Lupin Ltd. Novel method for preparation of crystalline perindopril erbumine
SI21703A (en) 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
JP4948392B2 (ja) * 2004-03-29 2012-06-06 レ ラボラトア セルビエ 固形薬学的組成物を調製するためのプロセス
WO2005108365A1 (en) * 2004-05-07 2005-11-17 Glenmark Pharmaceuticals Limited Processes for the preparation of alpha polymorph of perindopril erbumine
US20050250706A1 (en) * 2004-05-07 2005-11-10 Glenmark Pharmaceuticals Limited Processes for the preparation of alpha polymorph of perindopril erbumine
SI21800A (sl) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze perindoprila
SI21881A (sl) 2004-10-15 2006-04-30 Diagen, Smartno Pri Ljubljani, D.O.O. Nove kristalne oblike perindopril erbumin hidratov, postopek za njihovo pripravo in farmacevtske oblike, ki vsebujejo te spojine
SG125975A1 (en) * 2005-03-11 2006-10-30 Servier Lab New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
SG125976A1 (en) * 2005-03-11 2006-10-30 Servier Lab New gama crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
JP2006290825A (ja) * 2005-04-13 2006-10-26 Shiono Chemical Co Ltd アルファ型ペリンドプリルエルブミンの製造法
WO2007017894A2 (en) * 2005-05-05 2007-02-15 Arch Pharmalabs Limited PREPARATION OF NOVEL CRYSTALLINE η(ETA) FORM OF PERINDOPRIL ERBUMINE
US20070032661A1 (en) * 2005-08-03 2007-02-08 Glenmark Pharmaceuticals Limited Process for the preparation of intermediates of perindopril
MX2008002066A (es) * 2005-08-12 2008-04-16 Sandoz Ag Neuva forma cristalina de perindopril-erbumina.
AU2006281684B2 (en) * 2005-08-12 2012-08-02 Lek Pharmaceuticals D.D. A process for the preparation of perindopril erbumine
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
WO2007092758A2 (en) * 2006-02-03 2007-08-16 Dr. Reddy's Laboratories Ltd. Crystalline forms of perindopril erbumine
FR2897865B1 (fr) * 2006-02-28 2008-04-18 Servier Lab Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2897866B1 (fr) * 2006-02-28 2008-04-18 Servier Lab Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EA200600630A1 (ru) * 2006-04-20 2007-02-27 ИСМАГИЛОВ, Искандар Халиуллович ζ-ЗЕТА ФОРМА ПЕРИНДОПРИЛ ЭРБУМИНА
EP1964836A3 (en) * 2006-11-06 2008-11-19 IPCA Laboratories Limited A process for the preparation of perindopril erbumine in alpha crystalline form
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
EP2137148A1 (en) * 2007-03-22 2009-12-30 Aarti Healthcare Limited Process for the preparation of perindopril erbumine salt and novel polymorph (s) thereof
WO2008120241A2 (en) * 2007-03-29 2008-10-09 Ipca Laboratories Limited Novel alcohol solvates of perindopril erbumine
AU2013201812B2 (en) * 2007-06-27 2015-04-02 Les Laboratoires Servier Salts of perindopril
SI22543A (sl) 2007-06-27 2008-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove soli perindoprila
SI23149A (sl) 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
PT105315B (pt) 2010-09-29 2013-01-16 Inst Superior Tecnico Uma nova forma cristalina hidratada de erbumina de perindopril, métodos para a sua preparação e sua utilização em preparações farmacêuticas
CN103822996A (zh) * 2014-03-20 2014-05-28 东英（江苏）药业有限公司 一种培哚普利叔丁胺盐含量的测定方法
EP3842035A1 (en) 2019-12-23 2021-06-30 KRKA, d.d., Novo mesto Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2503155A2 (fr) * 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2620744A1 (fr) * 1987-09-17 1989-03-24 Degremont Procede de traitement par l'ozone de materiaux ligno-cellulosiques, notamment de pates a papier et reacteur pour la mise en oeuvre de ce procede
FR2620709B1 (fr) * 1987-09-17 1990-09-07 Adir Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
FR2620703B1 (fr) * 1987-09-17 1991-10-04 Adir Procede de synthese industrielle de l'acide perhydroindole carboxylique - 2(2s, 3as, 7as). application a la synthese de carboxyalkyl dipeptides
FR2771010B1 (fr) * 1997-11-19 2003-08-15 Adir Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un diuretique pour le traitement des desordres microcirculatoires
FR2811318B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811319B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105395497A (zh) * 2015-12-04 2016-03-16 杭州新诺华医药有限公司 一种稳定的α晶型培哚普利叔丁胺片及制备方法
CN105395497B (zh) * 2015-12-04 2019-06-18 杭州新诺华医药有限公司 一种稳定的α晶型培哚普利叔丁胺片及制备方法

Also Published As

Publication number Publication date
EA200300107A1 (ru) 2003-06-26
NO323447B1 (no) 2007-05-07
AP1537A (en) 2006-01-10
WO2001087835A1 (fr) 2001-11-22
KR20030024773A (ko) 2003-03-26
ZA200210092B (en) 2003-12-12
NZ523173A (en) 2004-04-30
EE200300001A (et) 2004-08-16
ATE258918T1 (de) 2004-02-15
CZ2003357A3 (cs) 2003-05-14
CA2415438C (fr) 2009-01-20
TR200400238T4 (tr) 2004-03-22
SK1492003A3 (en) 2003-06-03
US20030186896A1 (en) 2003-10-02
EP1296947B1 (fr) 2004-02-04
SK285714B6 (sk) 2007-06-07
AP2002002691A0 (en) 2002-12-31
EA005008B1 (ru) 2004-10-28
KR100513570B1 (ko) 2005-09-09
UA57188C2 (uk) 2003-06-16
CN1328259C (zh) 2007-07-25
ME00443B (me) 2011-10-10
HRP20030077B1 (en) 2011-07-31
YU100402A (sh) 2003-08-29
JP2003533507A (ja) 2003-11-11
ES2214434T3 (es) 2004-09-16
FR2811320A1 (fr) 2002-01-11
JP5016185B2 (ja) 2012-09-05
GEP20043361B (en) 2004-06-10
HK1055425A1 (en) 2004-01-09
JP2005047902A (ja) 2005-02-24
DE60101968D1 (de) 2004-03-11
JP3602826B2 (ja) 2004-12-15
NO20030024L (no) 2003-01-03
OA12304A (en) 2003-12-29
BG64868B1 (bg) 2006-07-31
DK1296947T3 (da) 2004-06-01
FR2811320B1 (fr) 2002-08-23
HRP20030077A2 (en) 2003-04-30
PL348492A1 (en) 2002-01-14
US20050059609A1 (en) 2005-03-17
EP1296947A1 (fr) 2003-04-02
AR034124A1 (es) 2004-02-04
EE05268B1 (et) 2010-02-15
PL206359B1 (pl) 2010-07-30
BR0112367A (pt) 2003-05-13
MXPA02012949A (es) 2003-05-15
AU7641801A (en) 2001-11-26
NO20030024D0 (no) 2003-01-03
RS50915B (sr) 2010-08-31
AU2001276418B2 (en) 2005-07-28
BG107532A (en) 2003-12-31
DE60101968T2 (de) 2004-12-23
CA2415438A1 (fr) 2001-11-22
PT1296947E (pt) 2004-05-31
CZ297672B6 (cs) 2007-02-28

Similar Documents

Publication Publication Date Title
CN1440387A (zh) α结晶形式的哌林多普利叔丁基胺盐
CN1440386A (zh) 新的γ结晶形式的哌林多普利叔丁基胺盐、其制备方法和包含它的药物组合物
CN1440388A (zh) 新的β结晶形式的哌林多普利叔丁基胺盐、其制备方法和包含它的药物组合物
CN1149994C (zh) 左西孟旦口服组合物
JP2013006839A (ja) ペリンドプリル
AU2007220435B2 (en) Alpha crystalline form of the arginine salt of perindopril, process for preparing it, and pharmaceutical compositions comprising it
US10696629B2 (en) Crystalline form of dextral oxiracetam, preparation method therefor and use thereof
US10556863B1 (en) Crystalline form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof
AU2006235841A1 (en) Novel beta crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C35 Partial or whole invalidation of patent or utility model
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20110930

Decision number of declaring invalidation: 17333

Granted publication date: 20070725